REVIEW part II

REFERENCES___________________________________________________________________________________

1. Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat Rev Neurosci. 2006;7(1):30-40.

2. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005;433(7027):760-764.

3. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90- 94.

4. Baruch K, Deczkowska A, David E, et al. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science. 2014;346(6205):89-93.

5. Katsimpardi L, Litterman NK, Schein PA, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344(6184):630-634.

6. Villeda SA, Plambeck KE, Middeldorp J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20(6):659-663.

7. Brack AS, Conboy MJ, Roy S, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007;317(5839): 807-810.

8. Sinha M, Jang YC, Oh J, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014;344(6184): 649-652.

9. Loffredo FS, Steinhauser ML, Jay SM, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153(4):828-839.

10. Egerman MA, Cadena SM, Gilbert JA, et al. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab. 2015;(May):18.

11. Salpeter SJ, Khalaileh A, Weinberg-Corem N, Ziv O, Glaser B, Dor Y. Systemic regulation of the age-related decline of pancreatic β-cell replication. Diabetes. 2013;62(8):2843-2848.

12. Keyes BE, Segal JP, Heller E, et al. Nfatc1 orchestrates aging in hair follicle stem cells. Proc Natl Acad SciUSA. 2013;110(51):E4950-E4959.

13. Baht GS, Silkstone D, Vi L, et al. Exposure to a youthful circulaton rejuvenates bone repair through modulation of β-catenin. Nat Commun. 2015;6:7131.

14. Ruckh JM, Zhao JW, Shadrach JL, et al. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell. 2012;10(1):96-103.

15. Aimone JB, Li Y, Lee SW, Clemenson GD, Deng W, Gage FH. Regulation and function of adult neurogenesis: from genes to cognition. Physiol Rev. 2014;94(4):991-1026.

16. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971–83.

17. Mallick P, Kuster B. Proteomics: a pragmatic perspective. Nat Biotechnol. 2010;28:695–709.

18. Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, Nelson SK, Williams S, Hodges A, Johnston C, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Newhouse S, Lovestone S, Dobson RJB. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis. 2014;38:515–31.

19. Jaeger PA, Villeda SA, Berdnik D, Britschgi M, Wyss-Coray T. Focused plasma proteomics for the study of brain aging and neurodegeneration. In: Coppola G, editor. The OMICS: Applications in Neuroscience. New York: Oxford Univ. Press; 2014. p. 183–91.

20. Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol. 2007;114:31–8.

21. Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, Nestor PJ, Patterson K. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain. 2010;133:300–6.

22. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, Criswell LA, Jaeger PA, Stan T, Heggeli KA, Hsu SC, Karydas A, Khan BK, Grinberg LT, Gorno-Tempini M-L, Boxer AL, Rosen HJ, Kramer JH, Coppola G, Geschwind DH, Rademakers R, Seeley WW, Wyss-Coray T, Miller BL. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatr. 2013;84:956–62.

23. La Joie R, Landeau B, Perrotin A, Bejanin A, Egret S, Pélerin A, Mézenge F, Belliard S, de La Sayette V, Eustache F, Desgranges B, Chételat G. Intrinsic connectivity identifies the hippocampus as a main crossroad between Alzheimer’sand semantic dementia-targeted networks. Neuron. 2014;81:1417–28.

24. Jaeger PA. Cytokine and Leukocyte Profiling Reveal Pro-Inflammatory and Autoimmune Features in Frontotemporal Dementia Patients. http://dx.doi.org/10.1101/049791.

25. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

26. de La Fuente A. From ‘differential expression’ to ‘differential networking’ – identification of dysfunctional regulatory networks in diseases. Trends Genet. 2010;26:326–33.

27. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863–8.

28. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.

29. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res.2009;37:1–13.

30. Lewis RD, Perry MJ, Guschina IA, Jackson CL, Morgan BP, Hughes TR. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. Am J Pathol. 2011;179:1601–7.

31. Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie T, Ono K, Takaya T, Takanabe-Mori R, Akao M, Abe M, Morimoto T, Murayama T, Yokode M, Fujita M, Shimatsu A, Hasegawa K. Distinct characteristics of circulating vascular endothelial growth factor-a and C levels in human subjects. PLoS ONE. 2011;

32, e29351. 17. Eickelberg O, Pansky A, Koehler E, Bihl M, Tamm M, Hildebrand P, Perruchoud AP, Kashgarian M, Roth M. Molecular mechanisms of TGF-(beta) Jaeger et al. Molecular Neurodegeneration (2016) 11:31 Page 16 of 18 antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J. 2001;15:797–806.

33. Strickertsson JAB, Døssing KBV, Aabakke AJM, Nilsson H-O, Hansen TVO, Knigge U, Kjær A, Wadström T, Friis-Hansen L. Interferon-γ inhibits ghrelin expression and secretion via a somatostatin-mediated mechanism. World J Gastroenterol. 2011;17:3117–25.

34. Shibanuma M, Mashimo J, Mita A, Kuroki T, Nose K. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochem. 1993;217:13–9.

35. Britschgi M, Rufibach K, Huang SLB, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol Cell Proteomics. 2011;10:M111. 008862.

36. Gjoneska E, et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature. 2015;518:365–369. [PMC free article] [PubMed]

37. Satoh JI, Asahina N, Kitano S, Kino Y. A comprehensive profile of ChIP-Seq-based PU.1/Spi1 target genes in microglia. Gene Regul Syst Bio. 2014;8:127–139. [PMC free article] [PubMed]

38. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194–1217. [PMC free article] [PubMed]

39. Ray S, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Med. 2007;13:1359–1362. [PubMed]

40. Menni C, et al. Circulating proteomic signatures of chronological age. J Gerontol A Biol. 2015;70:809–816. [PMC free article] [PubMed]

41. Baird GS, et al. Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am J Pathol. 2012;180:446–456. [PMC free article] [PubMed]

42. Hu WT, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79:897–905. erratum 79, 1935 (2012) [PMC free article] [PubMed]

43. Johnstone D, Milward EA, Berretta R, Moscato P. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset. PLoS ONE. 2012;7:e34341. [PMC free article] [PubMed]

44. Hye A, et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement. 2014;10:799–807. [PMC free article] [PubMed]

45. Soares HD, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol. 2012;69:1310–1317. [PMC free article] [PubMed]

46. Britschgi M, et al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol Cell Proteomics. 2011;10:M111.008862. [PMC free article][PubMed]

47. Kiddle SJ, et al. Plasma based markers of [¹¹C] PiB-PET brain amyloid burden. PLoS ONE. 2012;7:e44260. [PMC free article] [PubMed]

48. Sattlecker M, et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. 2014;10:724–734. [PubMed]

49. Jaeger PA, et al. Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener. 2016;11:31. erratum 11, 42 (2016) [PMC free article] [PubMed]

50. Villeda SA, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477:90–94. The first demonstration of the effects of circulatory blood factors on brain ageing and cognitive function and the first systematic treatment of ageing with plasma injections. [PMC free article] [PubMed]

51. Baruch K, et al. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc Natl Acad of Sci USA. 2013;110:2264–2269. [PMC free article][PubMed]

52. Vasudevan AR. Eotaxin and obesity. J Clin Endocrinol Metab. 2006;91:256–261. [PubMed]

53. Choi KM, et al. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol. 2007;157:437–442. [PubMed]

54. Smith LK, et al. β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nature Med. 2015;21:932–937. [PMC free article] [PubMed]

55. Shatz CJ. MHC class I: an unexpected role in neuronal plasticity. Neuron. 2009;64:40–45.[PMC free article] [PubMed]

56. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol. 2014;69:S4–S9. [PubMed]

57. Coppé JP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–68. [PMC free article] [PubMed]

58. Salminen A, et al. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci. 2011;34:3–11. [PubMed]